Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Value Investing -- Ignore unavailable to you. Want to Upgrade?

To: Lazarus who wrote (59934)	5/15/2018 1:00:24 PM
From: Lazarus	Respond to of 78730

IVRO - follow up. The quintessential nano-cap. Book value nearly .05 Plenty of cash Tiny bit of debt Managing to make $$ Quarterly report released today. Cash $ 421.000, assets 1.3 million, liabilities just $ 49,170 Net profit last Q $.002 per share ------ The CORROSITEX™ assay has been marketed since 1991 and the IRRITECTION® assays have been marketed since 1989. All three test methods are currently marketed by Company internal personnel through industry contacts, standard advertising and a strategic alliance with INT.E.G.RA, a division of Italy based Res Pharma, which sells and distributes the Company’s test kits and laboratory testing services in Italy and 21 other countries around the world. The Company is also in the process of developing a targeted social media marketing program. As a result of the OECD Expert Committee meeting in November 2017, the Company’s Ocular IRRITECTION® test method has now moved on to the next phase of the OECD adoption process for acceptance as a substitute for animal testing on all future cosmetic products.